Get the Stockscreener App
4.32
2.37%
0.10
After Hours:
4.31
-0.01
-0.23%
Trisalus Life Sciences Inc stock is traded at $4.32, with a volume of 94,405.
It is up +2.37% in the last 24 hours and down -8.67% over the past month.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
See More
Previous Close:
$4.22
Open:
$4.26
24h Volume:
94,405
Relative Volume:
0.20
Market Cap:
$265.32M
Revenue:
$45.15M
Net Income/Loss:
$-39.23M
P/E Ratio:
-2.3619
EPS:
-1.829
Net Cash Flow:
$-18.93M
1W Performance:
+0.23%
1M Performance:
-8.67%
6M Performance:
-17.24%
1Y Performance:
-5.26%
1-Day Range:
$4.12
$4.413
1-Week Range:
$4.00
$4.413
52-Week Range:
$2.20
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.32 | 259.18M | 45.15M | -39.23M | -18.93M | -1.829 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Lake Street | Buy |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
View All
Trisalus Life Sciences Inc Stock (TLSI) Latest News
TriSalus Life Sciences Inc (TLSI) Cash Flow - TradingKey
TriSalus Life Sciences Inc (TLSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TriSalus Life Sciences Inc (TLSI) Balance Sheet - TradingKey
TriSalus Life Sciences Inc (TLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
TLSI|TriSalus Life Sciences Inc|Price:4.220|Chg%:-0.050 - TradingKey
TriSalus Life Sciences, Inc. Revenue Breakdown – NASDAQ:TLSI - TradingView
TriSalus Life Sciences Inc (TLSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TriSalus Life Sciences Initiates PREDICTT Clinical Trial - Medical Product Outsourcing
Lobbying Update: $90,000 of TRISALUS LIFE SCIENCES lobbying was just disclosed - Quiver Quantitative
Press Release: TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call - Moomoo
TriSalus Life Sciences to host Q2FY26 financial results call - scanx.trade
TriSalus sets Aug. 6 webcast for second-quarter results - Stock Titan
TriSalus Life Sciences (TLSI) Holds Near Support Amid Modest Uptick – Biotech Sector in FocusAnchored VWAP - dars.gov.et
TriSalus Life Sciences (TLSI) Edges Higher as Stock Tests Key Resistance LevelsLow Risk Entry Stocks - dars.gov.et
Price to sales forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSI - TradingView
TriSalus Life Sciences, Inc. (TLSI) reports Q1 loss, lags revenue estimates - MSN
TLSIW SEC FilingsTriSalus Life Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
First Light Asset Management, Mathew Arens report 10.74% stake in TriSalus (TLSI) - Stock Titan
Form 4 TriSalus Life Sciences Inc For: 6 July By Investing.com - Investing.com Nigeria
TriSalus (TLSI) CFO has shares withheld to cover RSU tax obligations - Stock Titan
TriSalus Life Sciences, Inc. Warrant 2023-04.08.2028 on TriSalus Life Sciences Financial Disclosures & SEC Filings - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Scien - The National Law Review
TriSalus Life Sciences (TLSI) Stock Analysis Report | Financials & Insights - Benzinga
TriSalus (TLSI) CEO Mary Szela acquires 3,990 ESPP shares, now holds 1.08M - Stock Titan
TriSalus Life Sciences (TLSI) CCO acquires 561 ESPP shares - Stock Titan
Price to earnings forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSI - TradingView
Form 4 TriSalus Life Sciences Inc For: 29 June By Investing.com - Investing.com Canada
TriSalus Life Sciences (TLSI) CMO awarded RSUs and 120,000-share option grant - Stock Titan
TriSalus (TLSI) CMO discloses common stock and option holdings in Form 3 - Stock Titan
TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
TriSalus Life Sciences, Inc.(NasdaqGM: TLSI) dropped from Russell 3000 Value Benchmark - marketscreener.com
TriSalus Life Sciences, Inc.(NasdaqGM: TLSI) dropped from Russell 2500 Value Benchmark - marketscreener.com
TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) dropped from Russell 3000E Value Benchmark - marketscreener.com
TriSalus Life Sciences, Inc. Actuals & Estimates (NASDAQ:TLSI) - TradingView
TLSI Forecast — Price Target — Prediction for 2027 - TradingView
Canaccord reiterates TriSalus stock Buy rating after KOL event - Investing.com UK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc.TLSI - PR Newswire
Canaccord reiterates TriSalus stock Buy rating after KOL event By Investing.com - Investing.com Australia
CCORF Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
TriSalus Life Sciences Warrants (TLSIW) Dip 3.8% Toward Support as Trading Activity Remains LightDealer Gamma - dars.gov.et
TriSalus Life Sciences (TLSI) Gains 3.23% as Shares Test Resistance at $4.37Ichimoku Kumo Twist - dars.gov.et
Pomerantz investigates TriSalus over revenue dr... - Pluang
TriSalus Life Sciences Inc (TLSIW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TLSI News | TRISALUS LIFE SCIENCES INC (NASDAQ:TLSI) - ChartMill
TriSalus Life Sciences Inc (TLSIW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TriSalus Life Sciences Inc (TLSIW) Institutional Confidence - TradingKey
TriSalus Life Sciences Inc (TLSIW) Valuation: PE, PB & Fair Value Analysis - TradingKey
TriSalus Life Sciences Inc (TLSIW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):